Castle Biosciences, Inc. Common Stock (CSTL)

Price$20.39

Value ScoreC

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-62.38%

Price vs S&P 500 (4W)-24.82%

VGM Score45.54

Market Capitalization$597.80M

P/E Ratio (Annual)47.31x

All Metrics

P/CF (Annual)9.29x

Book Value / Share (Quarterly)$15.23

P/TBV (Annual)2.97x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)35.95%

Cash Flow / Share (Quarterly)$0.15

Price vs S&P 500 (YTD)-60.72%

Gross Margin (TTM)77.88%

Net Profit Margin (TTM)-3.78%

EPS (TTM)$-0.43

10-Day Avg Trading Volume0.38M

EPS Excl Extra (TTM)$-0.43

Revenue Growth (5Y)40.62%

EPS (Annual)$-0.83

ROI (Annual)-5.02%

Gross Margin (Annual)79.37%

Net Profit Margin (5Y Avg)-21.98%

Cash / Share (Quarterly)$8.64

Revenue Growth QoQ (YoY)-4.90%

EPS Growth (5Y)15.01%

P/E Normalized (Annual)47.31x

ROA (Last FY)-4.18%

Revenue Growth TTM (YoY)-2.06%

EBITD / Share (TTM)$-0.76

ROE (5Y Avg)-8.05%

Operating Margin (TTM)-9.79%

Cash Flow / Share (Annual)$0.95

P/B Ratio1.30x

P/B Ratio (Quarterly)1.61x

Net Income / Employee (Annual)$-27,400

EV / Revenue (TTM)1.61x

Net Interest Coverage (TTM)-3.43x

ROA (TTM)-2.30%

EV / EBITDA (TTM)132.43x

EPS Incl Extra (Annual)$-0.83

Current Ratio (Annual)5.26x

Quick Ratio (Quarterly)6.23x

3-Month Avg Trading Volume0.41M

52-Week Price Return21.14%

EV / Free Cash Flow (Annual)19.27x

Revenue / Employee (TTM)$385,000

Tangible BV / Share (Quarterly)$12.37

P/S Ratio (Annual)1.74x

Asset Turnover (Annual)0.59x

52-Week High$44.28

Operating Margin (5Y Avg)-27.32%

EPS Excl Extra (Annual)$-0.83

CapEx CAGR (5Y)49.96%

Tangible BV CAGR (5Y)35.03%

26-Week Price Return-48.79%

Quick Ratio (Annual)4.99x

13-Week Price Return-29.58%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)6.75x

Enterprise Value$545.73M

Revenue / Share Growth (5Y)29.09%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)-1.10%

Revenue / Employee (Annual)$389,800

Inventory Turnover (Annual)7.73x

Pretax Margin (Annual)-8.57%

Cash / Share (Annual)$10.09

3-Month Return Std Dev62.62%

Gross Margin (5Y Avg)80.12%

Net Income / Employee (TTM)$-14,500

EBITDA CAGR (5Y)17.49%

ROE (Last FY)-5.13%

Net Interest Coverage (Annual)-3.50x

EPS Basic Excl Extra (Annual)$-0.83

P/FCF (TTM)15.29x

Receivables Turnover (TTM)6.89x

EV / Free Cash Flow (TTM)120.79x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-0.43

Receivables Turnover (Annual)7.28x

ROI (TTM)-2.70%

P/S Ratio (TTM)1.76x

Pretax Margin (5Y Avg)-24.20%

Revenue / Share (Annual)$11.88

Tangible BV / Share (Annual)$12.87

Free OCF CAGR (5Y)40.79%

Price vs S&P 500 (52W)-7.01%

Year-to-Date Return-49.33%

5-Day Price Return-7.29%

EPS Normalized (Annual)$-0.83

ROA (5Y Avg)-7.04%

Net Profit Margin (Annual)-7.02%

Month-to-Date Return-6.50%

Cash Flow / Share (TTM)$-2.39

EBITD / Share (Annual)$-0.21

Operating Margin (Annual)-12.44%

LT Debt / Equity (Annual)0.02x

P/CF (TTM)12.39x

ROI (5Y Avg)-8.04%

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-0.43

P/TBV (Quarterly)1.98x

P/B Ratio (Annual)2.41x

Inventory Turnover (TTM)8.69x

Pretax Margin (TTM)-5.19%

Book Value / Share (Annual)$15.86

Price vs S&P 500 (13W)-40.25%

Net Margin Growth (5Y)-11.67%

Beta1.07x

P/FCF (Annual)21.10x

Revenue / Share (TTM)$11.37

ROE (TTM)-2.77%

52-Week Low$14.59

vGradeC

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.49est. -0.50

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.38

4.43

Industry Peers — Health Services(28)

Symbol	Value Score	Growth Score	Momentum Score	Price
CSTLCastle Biosciences, Inc. Common Stock	C	B	D	$20.39
NTRANatera, Inc. Common Stock	F	A	B	$211.85
DGXQuest Diagnostics Inc.	C	D	C	$193.67
LHLabcorp Holdings Inc.	C	D	C	$258.92
EXASExact Sciences Corp	F	B	A	$0.00
GHGuardant Health, Inc. Common Stock	F	A	A	$127.03
CAICaris Life Sciences, Inc. Common Stock	F	F	C	$15.48
CELCCelcuity Inc. Common Stock	—	—	C	$88.95
RDNTRadNet, Inc. Common Stock	D	C	D	$51.87
VCYTVeracyte, Inc.	D	A	B	$48.69
GRALGRAIL, Inc. Common Stock	D	A	C	$61.13

About

Castle Biosciences is a molecular diagnostics company specializing in gene expression profile tests for oncology and gastrointestinal conditions. Its product portfolio includes DecisionDx-Melanoma and DecisionDx-SCC for skin cancer risk assessment, MyPath Melanoma for melanoma diagnosis, and TissueCypher for monitoring esophageal cancer progression. The company generates revenue by delivering diagnostic test reports to healthcare providers treating patients with dermatologic cancers, uveal melanoma, and Barrett's esophagus.